GPR35; FFAR1; FFAR4; TAAR1; DRD4; ADRA2C; ADRA2A; | |
TSHR; NPSR1; CXCR1; NMUR2; | |
ALPI; PLA2G1B; TDP1; APOBEC3G; GLA; RECQL; P4HB; TERT; PIK3CG; PIK3R1; GLO1; HPGD; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; GFER; AKR1B10; NOX4; USP2; BRCA1; TNKS; PARP1; TNKS2; PYGL; APEX1; POLB; CD38; | |
PTPN1; PTPN11; | |
ACHE; GAA; | |
CHRNA7; | |
TOP2A; | |
AKT1; MET; GSK3B; NEK6; CSNK2A1; DAPK1; SYK; AXL; FLT3; CAMK2B; SRC; IGF1R; PTK2; AURKB; INSR; CDK1; MAPK1; PIM1; NUAK1; ALK; MYLK; NEK2; KDR; PKN1; | |
CA5B; CA5A; CA3; CA14; CA7; CA6; CA1; CA9; CA4; CA2; CA12; | |
NR1I2; | |
PPARA; PPARG; PPARD; | |
ESR2; | |
KDM4E; | |
MAOA; ALOX5; PTGS1; XDH; | |
CASP7; CASP1; | |
MMP13; MMP12; MMP3; MMP2; MMP9; MMP1; | |
BACE1; | |
TLR2; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
FUT7; | |
ABCC1; ABCG2; | |
LMNA; HSF1; FABP5; FABP2; FABP4; MAPT; FABP3; THPO; RAB9A; NPC1; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nicotinic acetylcholine receptor | CHRNA7 | Neuronal acetylcholine receptor protein alpha-7 subunit | P36544 | CHEMBL2492 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | PTPN11 | Protein-tyrosine phosphatase 2C | Q06124 | CHEMBL3864 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 | CHEMBL5857 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | HSF1 | Heat shock factor protein 1 | Q00613 | CHEMBL5869 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.044E-11 | 3.974E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.034E-11 | 3.974E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.892E-11 | 1.569E-08 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 9.030E-11 | 1.573E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS1, SRC |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.215E-09 | 1.664E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.214E-09 | 2.870E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 4.790E-09 | 5.543E-07 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3CG, PIK3R1, PTPN11, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.961E-09 | 5.656E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.125E-09 | 9.788E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.658E-08 | 1.650E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKN1, SYK |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.918E-08 | 1.881E-06 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, INSR, KDR, MAPK1, MET, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TOP2A, TP53 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 2.101E-08 | 2.043E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, SYK, TNKS |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.286E-08 | 3.010E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.313E-08 | 3.018E-06 | ADRA2A, AURKB, CA2, CA7, CD38, HIF1A, KDR, MAPK1, NEK2, NPC1, NPSR1, PARP1, PLA2G1B, SRC, SYK, TNKS, TNKS2 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.901E-08 | 5.140E-06 | AURKB, CA2, CA7, HIF1A, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 6.777E-08 | 5.810E-06 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1, TNKS |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 7.782E-08 | 6.646E-06 | AHR, CSNK2A1, HIF1A, HSF1, KDR, MAPT |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 8.627E-08 | 7.309E-06 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.071E-07 | 8.900E-06 | AXL, INSR, MET, NOX4, PIK3CG, PIK3R1, PTK2, PTPN11, SRC, THPO |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.635E-07 | 1.299E-05 | ADRA2A, AKT1, FFAR1, HIF1A, INSR, NOX4, PIK3R1, PPARG, PTPN11, PYGL |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.109E-07 | 1.606E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, HSF1, STAT6 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 6.402E-07 | 4.384E-05 | AKT1, HIF1A, LMNA, P4HB, PPARD, SRC, TERT, TP53 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 7.037E-07 | 4.729E-05 | IGF1R, INSR, PIK3R1, PTPN11 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 7.352E-07 | 4.911E-05 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 7.410E-07 | 4.934E-05 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 8.468E-07 | 5.488E-05 | IGF1R, INSR, KDR, PTK2, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.050E-06 | 6.684E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.090E-06 | 6.882E-05 | AHR, ESR2, NR1I2, PPARA, PPARD, PPARG |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.833E-06 | 1.088E-04 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AURKB, BRCA1, CAMK2B, CASP7, CDK1, CSNK2A1, ESR2, FABP5, GSK3B, HIF1A, HPGD, HSF1, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NR1I2, NUAK1, PARP1, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, PTPN11, RECQL, SMN1, SMN2, SRC, STAT6, TERT, TNKS, TOP2A, TP53, USP2 |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.918E-06 | 1.126E-04 | ADRA2A, ADRA2C, AHR, AXL, HIF1A, HSF1, NFKB1, P4HB, PIK3R1, PPARD, PPARG, TLR2, TOP2A, TP53, TTR |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.191E-06 | 1.276E-04 | AKT1, CYP1A2, HSF1, MAPK1, MMP9 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.250E-06 | 1.303E-04 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
MF | Unclassified; | GO:0004872; receptor activity | 2.370E-06 | 1.369E-04 | ADRA2A, ADRA2C, AHR, ALK, AXL, CHRNA7, CXCR1, DRD4, ESR2, FFAR1, FFAR4, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, NR1I2, PPARA, PPARD, PPARG, TAAR1, TLR2, TSHR |
MF | Unclassified; | GO:0032403; protein complex binding | 2.481E-06 | 1.429E-04 | ACHE, ADRA2A, APEX1, FLT3, IGF1R, INSR, KDR, MMP12, MMP13, MMP9, P4HB, PIK3R1, PPARA, PTPN1, PTPN11, SRC, SYK, TLR2, TSHR |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.232E-06 | 1.823E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 3.529E-06 | 1.960E-04 | ADRA2A, ADRA2C, AKT1, INSR, SRC |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 3.529E-06 | 1.960E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.701E-06 | 2.050E-04 | AHR, BRCA1, ESR2, NR1I2, PIM1, PPARA, PPARD, PPARG, SRC |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.778E-06 | 2.088E-04 | ALOX12, ALOX15, ALOX5, HPGD |
CC | GO:0044464; cell part | GO:0005829; cytosol | 4.714E-06 | 2.573E-04 | AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CDK1, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GFER, GLO1, GSK3B, HIF1A, HPGD, HSF1, LMNA, MAPK1, MAPT, MYLK, NEK2, NEK6, NFKB1, PIK3CG, PIK3R1, PIM1, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PTPN11, PYGL, RAB9A, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, XDH |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 4.749E-06 | 2.579E-04 | AHR, AXL, CSNK2A1, DRD4, GSK3B, PPARA, PPARG, SRC, TOP2A, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 5.881E-06 | 3.078E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 6.430E-06 | 3.340E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 7.327E-06 | 3.772E-04 | ADRA2C, ALOX12, APP, AXL, CD38, CHRNA7, FFAR4, GPR35, GSK3B, HIF1A, HSF1, LMNA, NFKB1, PIK3CG, PIK3R1, PPARD, PPARG, PTK2, PTPN11, TERT, TLR2, XDH |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 9.677E-06 | 4.822E-04 | ALOX15, APP, CHRNA7, FFAR4, KDR, NOX4, PTPN11, SRC, THPO |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 1.161E-05 | 5.708E-04 | AKT1, INSR, PIK3R1, PTPN11, TERT |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.209E-05 | 5.917E-04 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.470E-05 | 7.051E-04 | HPGD, MMP2, MMP9, TERT |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.782E-05 | 8.364E-04 | ADRA2A, ADRA2C, DRD4 |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.828E-05 | 8.501E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.965E-05 | 9.009E-04 | AKT1, FABP3, FFAR1, PPARG, SRC, TLR2 |
BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 2.024E-05 | 9.218E-04 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, HSF1, INSR, KDR, PPARA, PTK2, PTPN1 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.502E-05 | 1.098E-03 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 2.502E-05 | 1.098E-03 | HIF1A, HSF1, PPARD, TP53 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.660E-05 | 1.165E-03 | INSR, KDR, SYK |
BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 2.814E-05 | 1.218E-03 | ADRA2A, ADRA2C, FLT3, HSF1, PTPN1, SRC, SYK, TP53 |
BP | GO:0051179; localization | GO:0051924; regulation of calcium ion transport | 2.882E-05 | 1.245E-03 | ADRA2A, CAMK2B, DRD4, FFAR1, GPR35, MYLK, NPSR1, PIK3CG, PLA2G1B |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 3.433E-05 | 1.442E-03 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 3.433E-05 | 1.442E-03 | APP, GSK3B, IGF1R, PARP1 |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 3.436E-05 | 1.442E-03 | BRCA1, ESR2, NR1I2, PPARA, PPARD, PPARG, SRC |
MF | GO:0005488; binding | GO:0043621; protein self-association | 3.589E-05 | 1.500E-03 | ACHE, FLT3, HSF1, PPARG, TP53 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 3.650E-05 | 1.520E-03 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, APOBEC3G, CAMK2B, CHRNA7, FLT3, GLA, HPGD, MAPT, NFKB1, PYGL, TERT, TOP2A, XDH |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 3.780E-05 | 1.565E-03 | PPARG, SRC, TP53 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 3.780E-05 | 1.565E-03 | ABCC1, ABCG2, NR1I2 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 3.848E-05 | 1.577E-03 | AKT1, INSR, MAPT, NOX4, TP53, XDH |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 3.854E-05 | 1.577E-03 | APP, BACE1, CHRNA7, INSR, KDR, MAPK1, NPC1, SRC, STAT6, TLR2 |
BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 3.984E-05 | 1.613E-03 | AKT1, FABP3, PPARA, PPARG |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 3.984E-05 | 1.613E-03 | AKT1, MAPT, PTPN1, TP53 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 4.597E-05 | 1.837E-03 | AXL, IGF1R, INSR, PIK3R1 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 4.777E-05 | 1.888E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.777E-05 | 1.888E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.777E-05 | 1.888E-03 | ALOX12, ALOX15 |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 5.106E-05 | 2.003E-03 | ADRA2A, ADRA2C, ALK, AXL, CHRNA7, CXCR1, DRD4, FFAR1, FFAR4, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, PPARG, TAAR1, TSHR |
MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 5.526E-05 | 2.137E-03 | ESR2, NR1I2, PPARA, PPARD, PPARG |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 6.217E-05 | 2.367E-03 | APP, CDK1, MAPK1, PARP1, PIK3R1, TLR2 |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 6.217E-05 | 2.367E-03 | DRD4, PPARA, PPARG, TOP2A, TP53, USP2 |
BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 7.195E-05 | 2.720E-03 | APEX1, APP, CASP1, NOX4, PIK3CG, PPARG, TP53 |
BP | GO:0009987; cellular process | GO:0010648; negative regulation of cell communication | 7.410E-05 | 2.796E-03 | ACHE, ADRA2A, ADRA2C, AKT1, BRCA1, CD38, DAPK1, ESR2, GPR35, GSK3B, HIF1A, IGF1R, LMNA, MET, MMP12, MMP9, PPARG, PTPN1, PTPN11, SRC, TERT, XDH |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 7.751E-05 | 2.903E-03 | AKT1, INSR, PPARA, SRC |
BP | GO:0023052; signaling | GO:0023057; negative regulation of signaling | 7.755E-05 | 2.903E-03 | ACHE, ADRA2A, ADRA2C, AKT1, BRCA1, CD38, DAPK1, ESR2, GPR35, GSK3B, HIF1A, IGF1R, LMNA, MET, MMP12, MMP9, PPARG, PTPN1, PTPN11, SRC, TERT, XDH |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 7.844E-05 | 2.925E-03 | AKT1, APEX1, CA5A, CA5B, CASP1, CDK1, CYP1A1, CYP1B1, ESR2, GFER, GSK3B, HSD17B10, MAOA, MAPK1, MMP2, MPO, NFKB1, NOX4, PARP1, PTPN11, SRC, TP53 |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 8.210E-05 | 3.051E-03 | AKT1, BRCA1, DAPK1, LMNA, SRC, TERT |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 8.479E-05 | 3.145E-03 | ABCG2, ADRA2A, AHR, APP, CHRNA7, IGF1R, INSR, SYK, TLR2, TSHR |
BP | GO:0009987; cellular process | GO:0071280; cellular response to copper ion | 8.873E-05 | 3.253E-03 | CYP1A1, CYP1A2, HSF1 |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 1.006E-04 | 3.676E-03 | ALOX12, BRCA1, CHRNA7, CYP1B1, HIF1A, KDR, TERT |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 1.044E-04 | 3.801E-03 | AKR1B1, APEX1, GAA, HIF1A, NOX4, PARP1, PTPN11, SRC, TERT |
BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 1.098E-04 | 3.965E-03 | CA2, CD38, SRC, SYK |
BP | GO:0009987; cellular process | GO:0045742; positive regulation of epidermal growth factor receptor signaling pathway | 1.224E-04 | 4.371E-03 | ADRA2A, ADRA2C, AKT1, MMP9 |
CC | GO:0044464; cell part | GO:0005764; lysosome | 1.270E-04 | 4.459E-03 | AKR1B1, AKR1B10, GAA, GLA, MPO, NPC1, PIK3CG, RAB9A, SRC |
BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 1.361E-04 | 4.735E-03 | AKT1, CASP1, CASP7, PTK2 |
BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 1.365E-04 | 4.742E-03 | ALOX5, CXCR1, FABP5, GAA, GLA, MAPK1, MMP9, MPO, NFKB1, PYGL, TLR2, TTR |
BP | GO:0065007; biological regulation | GO:0051101; regulation of DNA binding | 1.371E-04 | 4.754E-03 | MMP9, NEK2, PARP1, PPARA, PPARG, TNKS |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 1.397E-04 | 4.838E-03 | TERT, TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 1.427E-04 | 4.876E-03 | APP, TLR2 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.427E-04 | 4.876E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.427E-04 | 4.876E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.427E-04 | 4.876E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.427E-04 | 4.876E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.427E-04 | 4.876E-03 | ALOX12, ALOX15 |
BP | GO:0032501; multicellular organismal process | GO:0032481; positive regulation of type I interferon production | 1.437E-04 | 4.882E-03 | MMP12, NFKB1, STAT6, SYK, TLR2 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.437E-04 | 4.882E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.510E-04 | 5.050E-03 | CYP19A1, FFAR4, NFKB1, PPARA, PPARD, PPARG |
MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 1.510E-04 | 5.050E-03 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 1.583E-04 | 5.271E-03 | AXL, FLT3, HIF1A, PKN1, POLB, PTPN11 |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.615E-04 | 5.368E-03 | ADRA2C, AKT1, APP, AXL, CA2, CAMK2B, HIF1A, KDR, MAPT, NFKB1, PARP1, PPARD, PPARG, SYK, TERT, THPO, TLR2 |
BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.665E-04 | 5.509E-03 | FLT3, HIF1A, KDR, L3MBTL1, MAPK1, PKN1, POLB |
BP | GO:0032502; developmental process | GO:0009653; anatomical structure morphogenesis | 1.833E-04 | 6.002E-03 | APP, AXL, CA2, CA9, CHRNA7, CYP1B1, GAA, HIF1A, HPGD, INSR, MAPK1, MET, MMP13, MMP2, MYLK, NOX4, POLB, PTK2, PTPN11, SRC, STAT6, SYK |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.856E-04 | 6.059E-03 | AXL, CDK1, CSNK2A1, FLT3, PPARG |
BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 1.993E-04 | 6.461E-03 | APP, CA2, CA7, CHRNA7, DRD4, MAPK1 |
BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 2.067E-04 | 6.639E-03 | AKT1, CYP1B1, TLR2 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 2.067E-04 | 6.639E-03 | CYP1A1, PPARD, PPARG |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.067E-04 | 6.639E-03 | CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 2.067E-04 | 6.639E-03 | AURKB, CDK1, PKN1 |
BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 2.097E-04 | 6.697E-03 | CAMK2B, GSK3B, HSF1, MAPK1, MAPT |
BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 2.216E-04 | 6.981E-03 | AXL, CASP1, HIF1A, MMP12 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 2.299E-04 | 7.203E-03 | AKT1, AURKB, BRCA1, CSNK2A1, L3MBTL1, NUAK1, TP53 |
BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 2.379E-04 | 7.388E-03 | CD38, CYP19A1, FFAR1, HIF1A, PPARD, PTPN11 |
BP | GO:0032501; multicellular organismal process | GO:0010634; positive regulation of epithelial cell migration | 2.379E-04 | 7.388E-03 | AKT1, HIF1A, KDR, MET, MMP9, SRC |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 2.424E-04 | 7.477E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 2.468E-04 | 7.580E-03 | AKT1, HIF1A, TERT |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 2.646E-04 | 8.055E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 2.652E-04 | 8.055E-03 | CASP1, CASP7, MAPT, PPARG, XDH |
BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 2.840E-04 | 8.448E-03 | NMUR2, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.840E-04 | 8.448E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.840E-04 | 8.448E-03 | ADRA2A, ADRA2C |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.840E-04 | 8.448E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.840E-04 | 8.448E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 2.840E-04 | 8.448E-03 | APP, INSR |
BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 2.985E-04 | 8.784E-03 | AKT1, ALK, APP, ESR2, NFKB1, PLA2G1B, PPARG, TLR2 |
CC | GO:0043226; organelle | GO:0000784; nuclear chromosome, telomeric region | 3.064E-04 | 8.991E-03 | APEX1, CDK1, PARP1, TERT, TNKS, TNKS2 |
BP | GO:0065007; biological regulation | GO:0032092; positive regulation of protein binding | 3.135E-04 | 9.151E-03 | APP, GSK3B, HSF1, MMP9, TERT |
BP | GO:0009987; cellular process | GO:1901215; negative regulation of neuron death | 3.218E-04 | 9.355E-03 | AKT1, AXL, GSK3B, HIF1A, HSF1, PPARA, TERT |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.218E-04 | 9.355E-03 | ABCC1, ADRA2A, CA2, CA4, CA9, HPGD, TSHR |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 3.413E-04 | 9.793E-03 | AHR, PPARA, TERT |
BP | GO:0008152; metabolic process | GO:0045892; negative regulation of transcription, DNA-templated | 3.477E-04 | 9.962E-03 | AHR, AURKB, BRCA1, CD38, ESR2, FABP4, HSF1, L3MBTL1, MMP12, NFKB1, NR1I2, PARP1, PPARA, PPARD, PPARG, SRC, STAT6, TP53, USP2 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.571E-21 | 3.801E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.447E-15 | 3.378E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.565E-14 | 1.273E-11 | ALPI, APOBEC3G, BRCA1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, GLO1, L3MBTL1, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, NR1I2, PARP1, PPARA, PPARD, PPARG, PTPN1, TNKS, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.004E-14 | 1.362E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 9.611E-21 | 1.893E-18 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.978E-13 | 4.903E-11 | CAMK2B; SRC; MMP2; PTPN11; PIK3R1; HIF1A; MMP9; PTK2; PIK3CG; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.748E-10 | 1.148E-08 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PIK3CG; PTK2; IGF1R; AKT1; MAPK1; PPARG; MET; TP53; PPARD |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.184E-09 | 4.664E-08 | GSK3B; SYK; INSR; PIK3R1; BRCA1; PTK2; NFKB1; PIK3CG; IGF1R; KDR; AKT1; MAPK1; PKN1; TP53; MET; TLR2 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.124E-09 | 1.016E-07 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG; PPARD |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.155E-09 | 1.016E-07 | PTPN1; GSK3B; INSR; AKT1; PTPN11; PIK3R1; PYGL; PPARA; NFKB1; PIK3CG |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.117E-09 | 1.016E-07 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.143E-10 | 3.518E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.206E-09 | 1.796E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.539E-08 | 2.756E-07 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; PIK3CG |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.746E-08 | 4.162E-07 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1; ESR2; PIK3CG |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 9.625E-09 | 1.896E-07 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.059E-08 | 4.305E-07 | CAMK2B; INSR; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; PIK3CG; IGF1R |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 5.312E-08 | 6.156E-07 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; PIK3CG; TLR2 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.640E-08 | 4.780E-07 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.951E-08 | 3.203E-07 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.183E-07 | 1.104E-06 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; PIK3CG; MYLK; IGF1R |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.067E-08 | 5.008E-07 | ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.158E-07 | 1.104E-06 | CAMK2B; GSK3B; AKT1; MAPK1; PTPN11; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.473E-07 | 1.262E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.233E-07 | 1.104E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2; PIK3CG |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 9.134E-08 | 9.470E-07 | FABP4; INSR; AKT1; PIK3R1; TSHR; PIK3CG; PTGS1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.732E-08 | 8.462E-07 | CYP2C9; CYP2C8; CHRNA7; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.258E-07 | 1.779E-06 | INSR; AKT1; PPARG; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.822E-07 | 2.510E-06 | PLA2G1B; INSR; KDR; AKT1; MAPK1; PTPN11; PIK3R1; MET; NFKB1; PIK3CG; IGF1R |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.671E-07 | 1.372E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2; PIK3CG |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.608E-07 | 1.976E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; PIK3CG; IGF1R |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.334E-07 | 2.754E-06 | CASP7; PARP1; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.377E-07 | 2.301E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; ESR2; PIK3CG |
hsa05162 | Measles_Homo sapiens_hsa05162 | 3.388E-07 | 2.301E-06 | GSK3B; CSNK2A1; AKT1; RAB9A; PIK3R1; TP53; NFKB1; PIK3CG; TLR2 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.901E-07 | 2.117E-06 | AKT1; MAPK1; PTPN11; PIK3R1; MET; HIF1A; PIK3CG |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.087E-06 | 5.790E-06 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.598E-07 | 4.158E-06 | CASP7; MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1; PIK3CG |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.819E-07 | 2.966E-06 | AKT1; MAPK1; PIK3R1; TP53; MET; PIK3CG; IGF1R |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.295E-06 | 1.077E-05 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2C9; CYP2C8; FUT7; AKR1B10; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; CD38; ALPI; XDH |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.838E-07 | 3.383E-06 | AKT1; MAPK1; PTPN11; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 5.838E-07 | 3.383E-06 | GSK3B; SYK; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.670E-06 | 8.222E-06 | SYK; SRC; AKT1; MAPK1; PIK3R1; PIK3CG; MYLK; PTGS1 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.297E-06 | 6.552E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A; PIK3CG |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.413E-07 | 3.609E-06 | PTPN1; CSNK2A1; SRC; INSR; MAPK1; MET; IGF1R |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.194E-06 | 1.430E-05 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1; PIK3CG |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.814E-06 | 1.981E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2; PIK3CG |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.276E-06 | 2.081E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 4.438E-06 | 1.901E-05 | PTPN1; GSK3B; INSR; AKT1; MAPK1; PIK3R1; PYGL; PIK3CG |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 5.767E-06 | 2.228E-05 | SYK; CXCR1; INSR; AKT1; MAPK1; PTPN11; PIK3R1; PIK3CG |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 8.183E-06 | 3.042E-05 | GSK3B; CASP7; INSR; AKT1; PIK3R1; PPARA; NFKB1; PIK3CG |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.012E-05 | 3.626E-05 | POLB; SYK; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.275E-05 | 4.486E-05 | SRC; INSR; KDR; AKT1; MAPK1; PIK3R1; MET; PIK3CG; IGF1R |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 9.856E-06 | 3.595E-05 | CAMK2B; ACHE; CHRNA7; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.278E-06 | 6.552E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; PIK3CG |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.994E-06 | 9.580E-06 | ALK; AKT1; MAPK1; PIK3R1; TP53; PIK3CG |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.706E-05 | 5.696E-05 | INSR; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A; PIK3CG; MYLK |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.472E-05 | 5.086E-05 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG; TLR2 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.642E-05 | 5.578E-05 | ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.653E-06 | 1.599E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; PIK3CG |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 3.044E-05 | 9.831E-05 | SYK; AKT1; MAPK1; PPARG; PIK3R1; NFKB1; PIK3CG |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.963E-05 | 1.780E-04 | CAMK2B; AKT1; MAPK1; PIK3R1; PPARA; NFKB1; TSHR; PIK3CG |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.282E-06 | 2.081E-05 | AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.136E-05 | 1.557E-04 | CDK1; AKT1; MAPK1; PIK3R1; PIK3CG; IGF1R |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.828E-06 | 1.981E-05 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.458E-06 | 1.126E-05 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 9.534E-05 | 2.538E-04 | THPO; PIM1; AKT1; STAT6; PTPN11; PIK3R1; PIK3CG |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 9.534E-05 | 2.538E-04 | CAMK2B; SRC; CD38; MAPK1; PIK3R1; PIK3CG; MYLK |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.855E-06 | 2.597E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.450E-05 | 8.043E-05 | AKT1; PIK3R1; TP53; NFKB1; PTK2; PIK3CG |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 7.968E-05 | 2.243E-04 | AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG; TLR2 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 7.166E-05 | 2.046E-04 | AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG; TLR2 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 7.166E-05 | 2.046E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.795E-04 | 4.321E-04 | ABCC1; PIM1; CYP1B1; MAPK1; BRCA1; TP53; MMP9; MET; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.398E-04 | 3.576E-04 | BACE1; APP; GSK3B; CASP7; MAPK1; MAPT; HSD17B10 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.798E-04 | 4.321E-04 | GSK3B; CASP1; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.540E-04 | 8.017E-04 | POLB; GSK3B; TERT; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.997E-04 | 4.682E-04 | CAMK2B; SYK; SRC; AKT1; MAPK1; NFKB1; TLR2 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.442E-04 | 3.641E-04 | MMP2; PTPN11; PIK3R1; MMP9; PTK2; PIK3CG |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 5.666E-04 | 1.200E-03 | GPR35; CHRNA7; NMUR2; ADRA2C; TAAR1; ADRA2A; DRD4; TSHR |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.764E-04 | 6.407E-04 | INSR; AKT1; MAPK1; PIK3R1; PIK3CG; IGF1R |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.891E-04 | 4.488E-04 | INSR; AKT1; PPARG; PIK3R1; PIK3CG; IGF1R |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 3.927E-04 | 8.792E-04 | GSK3B; AKT1; MAPK1; PIK3R1; PIK3CG; IGF1R |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.559E-03 | 3.134E-03 | CSNK2A1; CDK1; PTPN11; TP53; NFKB1; TLR2 |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 3.229E-03 | 6.058E-03 | SRC; MAPK1; PIK3R1; PTK2; PIK3CG; MYLK |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 9.309E-05 | 2.538E-04 | SYK; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 3.043E-02 | 4.684E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 3.224E-03 | 6.058E-03 | CAMK2B; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 5.090E-05 | 1.557E-04 | AKT1; MAPK1; PIK3R1; HIF1A; PIK3CG |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.698E-03 | 5.160E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.873E-02 | 4.492E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 2.167E-03 | 4.226E-03 | SYK; MAPK1; PTPN11; PIK3R1; PIK3CG |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 3.311E-02 | 4.979E-02 | CXCR1; THPO; FLT3; KDR; MET |
hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 3.306E-02 | 4.979E-02 | CAMK2B; CHRNA7; CD38; MYLK |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 6.956E-05 | 2.045E-04 | INSR; AKT1; PIK3R1; PIK3CG; IGF1R |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 5.167E-04 | 1.118E-03 | CAMK2B; SRC; ALOX12; PIK3R1; PIK3CG |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.776E-03 | 3.498E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 9.470E-03 | 1.640E-02 | CAMK2B; CDK1; MAPK1; IGF1R |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 4.061E-04 | 8.988E-04 | SYK; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 5.931E-04 | 1.243E-03 | AKT1; MAPK1; PIK3R1; HIF1A; PIK3CG |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 5.667E-04 | 1.200E-03 | PIK3R1; NFKB1; PTK2; PIK3CG; TLR2 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.056E-02 | 1.794E-02 | GSK3B; MAPK1; MET; PTK2 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.970E-02 | 4.607E-02 | CAMK2B; GSK3B; MAPK1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.787E-04 | 4.321E-04 | SRC; PIK3R1; MET; PTK2; PIK3CG |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.306E-04 | 3.424E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 4.765E-03 | 8.612E-03 | CAMK2B; AKT1; PYGL; PPARA |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.675E-02 | 4.216E-02 | CA2; PLA2G1B; CD38 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 9.309E-05 | 2.538E-04 | CXCR1; SRC; PTPN11; MET; NFKB1 |
hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 2.264E-02 | 3.625E-02 | MMP1; MMP3; TLR2 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 3.283E-03 | 6.102E-03 | CAMK2B; SRC; MMP2; MAPK1 |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 2.135E-02 | 3.447E-02 | THPO; FLT3; CD38 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 3.330E-05 | 1.058E-04 | CASP7; HSF1; CASP1; NFKB1; TLR2 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.135E-02 | 3.447E-02 | SRC; CDK1; MAPK1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.550E-03 | 6.476E-03 | SYK; CSNK2A1; PARP1; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.676E-03 | 5.160E-03 | CASP1; MAPK1; PKN1; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.300E-02 | 2.171E-02 | MAPK1; NFKB1; TLR2 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.349E-02 | 2.233E-02 | CAMK2B; CA2; MYLK |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.621E-03 | 3.226E-03 | CASP7; CASP1; MAPK1; NFKB1 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.255E-03 | 2.575E-03 | AKT1; PTPN11; PPARA; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.207E-02 | 2.032E-02 | CA2; CYP3A4; ABCG2 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 9.492E-03 | 1.640E-02 | SRC; MAPK1; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 9.492E-03 | 1.640E-02 | STAT6; NFKB1; TLR2 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 6.610E-03 | 1.184E-02 | CASP1; MAPK1; NFKB1 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 7.273E-03 | 1.291E-02 | AKR1B10; AKR1B1; GLA |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.983E-04 | 6.833E-04 | INSR; MAPK1; PIK3R1; PIK3CG |
hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 3.082E-02 | 4.706E-02 | FABP2; PLA2G1B |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.321E-04 | 3.424E-04 | INSR; MAPK1; PIK3R1; PIK3CG |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 3.398E-03 | 6.256E-03 | AKT1; PIK3R1; PIK3CG |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.612E-05 | 1.442E-04 | AKR1B10; GAA; AKR1B1; GLA |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.460E-04 | 3.641E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.938E-02 | 3.182E-02 | AKR1B10; AKR1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.419E-02 | 3.844E-02 | AKR1B10; AKR1B1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.459E-04 | 1.962E-03 | MAPK1; PPARG; TP53 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.385E-03 | 2.813E-03 | POLB; PARP1; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.028E-02 | 1.761E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.397E-04 | 9.625E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
NA: NA | HIV infections | NA | AHR |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
NA: NA | Geographic retinal atrophy | NA | APP |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | CHRNA7; APP |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; PARP1; KDR; KDR; KDR; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; INSR |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
C00-D49: Neoplasms | Metastasis | C00-C97 | HSF1; AXL |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TERT; FLT3; MMP2; TLR2; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; INSR; ACHE; PTGS1; IGF1R; CDK1; ADRA2C; ADRA2A |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; CHRNA7; MAOA; ACHE |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; KDR; APP |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; ALOX5; MMP12; PPARD |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PIK3CG; KDR |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; PIK3CG; PIK3CG; INSR; HIF1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; PPARD |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | HSF1; AKR1B1; PTGS1 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1 |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; AXL; KDR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; PPARG; PPARD; PPARD |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; HSF1; AKR1B1; PTPN1; INSR; GSK3B; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
C00-D49: Neoplasms | Cancer | C00-C96 | CA9; AKT1; MET; HSF1; CSNK2A1; SYK; PIK3CG; CA1; FLT3; FLT3; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; PARP1; CD38; TLR2; TP53; KDR; APP |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3; PARP1 |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | HSF1; KDR |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; SYK; PIK3CG; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TLR2; TP53; KDR; KDR; KDR; TOP2A |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; TP53; TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
NA: NA | Dyslipidemia | NA | PPARD |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
NA: NA | Enthesopathy | NA | PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRNA7; CHRNA7; CHRNA7; DRD4 |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
NA: NA | Edema | NA | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Prostate cancer | C61 | TERT; PIK3CG; FLT3; TLR2 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
NA: NA | Rheumatold arthritis | NA | PTGS1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ALOX5; SYK; CASP1; MMP3; CAMK2B; MMP1 |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | HSF1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; MYLK; CA2 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRNA7; ADRA2C; NPSR1; APP |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; CD38; TP53 |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRNA7; CHRNA7; MAOA; MAPT; INSR; ACHE; ACHE; ACHE; GSK3B; ADRA2C; PPARG; PPARG; APP |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; TERT; CYP19A1; PIK3CG; INSR; FLT3; FLT3; IGF1R; CDK1; KDR; KDR; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRNA7; MAPT; ACHE |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
A00-B99: Certain infectious and parasitic diseases | Herpes simplex virus infection | B00 | HSF1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CHRNA7; MAPT; PPARD |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | CHRNA7 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
NA: NA | Angioedema | NA | PIK3CG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; CAMK2B; ACHE; CYP3A4 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; PPARG; PPARD |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PTPN1; PTPN1; PIK3CG; PIK3CG; INSR; NFKB1; PPARG; PPARG; PPARD |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | PIK3CG; CYP2C9 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRNA7 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; PIK3CG; MMP12; PTGS1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT; SRC; IGF1R; CD38 |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | TERT; PARP1; TLR2; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR; TLR2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | CHRNA7; ADRA2A |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PIK3CG; MMP1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRNA7; PLA2G1B; ALOX5; ALOX5; SYK; SYK; MMP12; ADRA2C |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
NA: NA | Colour dead tissues | NA | PTPN1 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; HSF1; FLT3 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |